Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Hims & Hers introduces affordable compounded GLP-1 drugs amid FDA warnings

By Brian Buntz | May 20, 2024

GLP-1 from Hims & HersHims & Hers Health Inc., an online pharmacy platform founded in 2017, said it would offer compounded GLP-1 drugs with the same active ingredient (semaglutide) as Novo Nordisk’s mega-blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy, at a significantly lower price of $199 per month.

This represents an 85% discount compared to the branded versions which cost around $1,350 per month without insurance. Yet FDA has warned against using compounded versions of these drugs, stating that the agency does not review them for safety, effectiveness, or quality. The FDA has received adverse event reports associated with compounded semaglutide products.

Novo Nordisk has also filed lawsuits against some compounding pharmacies, alleging they are offering contaminated or subpotent versions of semaglutide. Novo Nordisk holds the exclusive patent on semaglutide.

While Hims & Hers does not offer online ketamine therapy, compounding pharmacies provide compounded ketamine formulations to telehealth companies like MindBloom and Joyous. The FDA has also released a warning about this practice as well.

Hims & Hers does, however, offer mental health services like online therapy and prescriptions of traditional antidepressants for anxiety and depression.

Hims & Hers says it is working with an FDA-registered 503B outsourcing facility that complies with good manufacturing practices, after vetting potential suppliers for more than a year. The company plans to offer branded GLP-1 drugs once supply is consistently available.

According to the press release, Hims & Hers expects its weight loss offerings to top $100 million in revenue by the end of 2025, growing faster than any specialty in the company’s history.

Hims & Hers notes in the press release that medical providers on their platform determine what medications are medically appropriate and necessary for each patient. They also state that oral medication kits and compounded GLP-1 injections are not available in all states.

The press release highlights the company’s partnership with a leading US manufacturer of generic and 503B compounded injectable medications. Hims & Hers believes there is no one-size-fits-all approach to health and wellness treatments, and their platform is built on this belief.

Historically, some of the best-selling products from Hims & Hers are erectile dysfunction treatments like sildenafil (generic Viagra) and hair loss treatments such as minoxidil, finasteride, and specialized shampoos. It sells birth control pills and other women’s health products under its “Hers” brand.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE